KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:开放图源暂不可得 入排置信度 0.98

Efficacy and safety of novel fixed dose combination of vilanterol, glycopyrronium, and fluticasone furoate dry powder inhaler: A phase 3, randomized, non-inferiority trial compared with fixed dose combination of indacaterol, glycopyrronium, and mometasone furoate dry powder inhaler in Indian asthma patients.

Chintan Patel, Vaishal Sheth, Ravi Koppula, Avadhesh Kumar, Amit S Bhate, Diptikant Sahoo, Manish Kumar Jain, Asish Mondal, Deven Parmar, Kevinkumar Kansagra, Rahul Shrivastava, Hardik Pathak

Respir Med 247 108293

PMID40759266
PMCID-
DOI10.1016/j.rmed.2025.108293
发表日期2025-08-04
入排依据:未发现恶性肿瘤人群证据。
PubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。
摘要

摘要

BACKGROUND: For managing persistent asthma, M/s. Zydus Healthcare Limited has developed a novel fixed dose combination (FDC) of vilanterol 25 μg, glycopyrronium 50 μg, and fluticasone furoate 200 μg (VIL-GLY-FF) in dry powder inhaler (DPI) formulation. METHODS: This phase 3, multicenter, parallel group, open-label study randomized (1:1) patients not controlled with medium or high-dose inhaled corticosteroid in either the test (VIL-GLY-FF DPI) or reference (approved FDC DPI of indacaterol 150 μg, GLY 50 μg, and mometasone furoate 160 μg [IND-GLY-MF]) group. FDCs were administered by inhaling one capsule via Respihaler device once-daily for 12 weeks. The primary endpoint was the change in trough forced expiratory volume in 1 s (FEV1) at week 12 from baseline. Secondary outcomes included the comparison of trough forced vital capacity (FVC), post-bronchodilator FEV1 and FVC, and asthma control test score between the two groups. FINDINGS: All 256 enrolled patients completed the study. The least square mean (standard error) change in trough FEV1 at week 12 from baseline was 392.77 (31.33) ml and 364.34 (31.33) ml for the test and reference groups (p = 0.522), respectively. The lower limit of 95 % confidence interval for the difference between two groups for the mean change in trough FEV1 at week 12 from baseline was -58.83 ml, well-above the predefined non-inferiority margin (-150 ml). Other secondary endpoints and safety were comparable between the two groups. INTERPRETATION: VIL-GLY-FF DPI was found non-inferior to IND-GLY-MF DPI in improving trough FEV1 response. The test FDC was well-tolerated in Indian patients with persistent asthma. CLINICAL TRIAL REGISTRATION NUMBER: CTRI/2024/02/063046 (Clinical Trial Registry - India).

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。